Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report

doi:10.4251/wjgo.v12.i9.1065

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4829)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

289

WORD

162

HTML

2238

Figures (1-4)

230

Sum=2919

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

652

Download

1258

Sum=1910

Sep 15, 2020 (publication date) through Jul 24, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Sep 15, 2020; 12(9): 1065-1072
Published online Sep 15, 2020. doi: 10.4251/wjgo.v12.i9.1065

Full Size Figure Download Figure

Figure 3 Serial circulating tumor DNA testing for monitoring lapatinib treatment. A: Human epidermal growth factor receptor 2 (HER2) amplification on May 29, 2018; B: HER2 copy number alterations disappeared after lapatinib treatment on Sep 13, 2018; C: HER2 amplification was detected during disease progression on Mar 12, 2019; D: Mutant allele frequency of APC, TP53, and PIK3CA during lapatinib treatment. HER2: Human epidermal growth factor receptor 2; APC: Adenomatous polyposis coli; TP53: tumor protein 53; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Citation: Guan JL, Liu JH, Wang Q, Cong YW, Chen YX, Huang KF, Huang ML, Huang L. Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report. World J Gastrointest Oncol 2020; 12(9): 1065-1072
URL: https://www.wjgnet.com/1948-5204/full/v12/i9/1065.htm
DOI: https://dx.doi.org/10.4251/wjgo.v12.i9.1065